JPA: System, Multipurpose For In Vitro Coagulation Studies
What it covers
A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.
The identification in 21 CFR 864.5425, multipurpose system for in vitro coagulation studies. FDA gives JPA no definition of its own, so the regulation’s describes it.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K253658 | STA Satellite Max® | Diagnostica Stago, Inc. | Apr 27, 2026 | Traditional |
| K250965 | Automated Blood Coagulation Analyzer CN-Series (CN-6000) | Sysmex America, Inc. | Jun 2, 2025 | Traditional |
| K251024 | TEG 6s Hemostasis System Citrated: K, KH, RT, FF Assay Cartridge | Haemonetics | Apr 30, 2025 | Special |
| K243858 | TEG 6s Hemostasis System Citrated: K, KH, RT, FF Assay Cartridge | Haemonetics Corporation | Jan 15, 2025 | Special |
| K232018 | Citrated: K, KH, RTH, FFH | Haemonetics Corporation | Mar 29, 2024 | Traditional |
| K233790 | ACL TOP 970 CL | Instrumentation Laboratory | Dec 29, 2023 | Special |
| K221359 | ACL TOP 970 CL, HemosIL CL Anti-Cardiolipin IgM, HemosIL CL Anti-ß2 Glycoprotein-I IgM | Instrumentation Laboratory CO | Sep 29, 2023 | Traditional |
| K212183 | STA R Max 3, STA Compact Max 3 | Diagnostica Stago S.A.S | Jun 7, 2023 | Traditional |
| K201440 | ROTEM sigma Thromboelastometry System | Tem Innovations GmbH | Jul 8, 2022 | Traditional |
| K202101 | GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+), GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR), directCHECK ACT+ Whole Blood Control, Level 1 and Level 2, directCHECK ACT-LR Whole Blood Control, Level 1 and Level 2 | Accriva Diagnostics, Inc. | Dec 29, 2021 | Traditional |
Clearances by year
28 JPA 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 1 | 158 |
| 2025 | 3 | 30 |
| 2024 | 1 | 266 |
| 2023 | 3 | 506 |
| 2022 | 1 | 767 |
| 2021 | 1 | 518 |
| 2019 | 3 | 175 |
| 2018 | 1 | 219 |
| 2017 | 4 | 117 |
| 2016 | 6 | 114 |
| 2015 | 2 | 99 |
| 2013 | 1 | 29 |
| 2011 | 1 | 433 |
Who submits
15 applicants cleared a JPA device since 2011. 46% of the clearances went to applicants in United States, then Germany (36%), France (7%) and Spain (4%). By type: Traditional 71% and Special 29%.
| Applicant | Clearances since 2011 |
|---|---|
| Siemens Healthcare Diagnostics Products GmbH | 6 |
| Haemonetics Corporation | 4 |
| Accriva Diagnostics, Inc. | 2 |
| Diagnostica Stago S.A.S | 2 |
| Instrumentation Laboratory CO | 2 |
| Siemens Healthcare Diagnostic Products GmbH | 2 |
| Tem Innovations GmbH | 2 |
| Coramed Technologies, LLC | 1 |
How FDA classifies it
Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
From 21 CFR 864.5425. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 864.5425 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent JPA clearances declared.
Ask about JPA
Questions about JPA
What is FDA product code JPA?
Product code JPA, “System, Multipurpose For In Vitro Coagulation Studies” in FDA's classification database, is a Class II device type under 21 CFR 864.5425 (multipurpose system for in vitro coagulation studies), reviewed by FDA's Hematology panel. FDA's 510(k) database lists 181 clearances under JPA, 28 of them since 2011.
How many 510(k) clearances are there under JPA?
FDA’s 510(k) database listed 181 clearances under JPA as of Oct 29, 2026, 28 of them decided since 2011; the most recent decision was Apr 27, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a JPA 510(k)?
For the 4 JPA clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 47 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most JPA clearances?
Since 2011: Siemens Healthcare Diagnostics Products GmbH (6), Haemonetics Corporation (4), Accriva Diagnostics, Inc. (2), Diagnostica Stago S.A.S (2) and Instrumentation Laboratory CO (2). 15 applicants have cleared a JPA device in that time.